Category: Fellows Posters
The use of daily Emtricitabine (FTC)-tenofovir disoproxil fumarate (TDF) for Pre-Exposure Prophylaxis (PrEP) is effective for reducing HIV infections in high risk groups. However, there are many barriers patients experience when accessing PrEP. Follow-up care requires HIV testing every three months and routine monitoring of kidney function. For an otherwise healthy young person, these regular clinic appointments are burdensome. To resolve these barriers, we will pilot a phone clinic model for PrEP services. The goals of the program will be to make PrEP easily and rapidly accessible for any patient interested, and make follow up PrEP services more convenient.
This study has been submitted to our Institutional Review Board for approval. The electronic medical record system will identify adult patients who have received a FTC-TDF for PrEP prescription in the last 6 months, who are not managed by us for comorbid conditions, and have CrCl ≥ 60 mL/min. The following data will be collected: patient age, gender, vitals, HIV status, serum creatinine, current medications, reported adverse medication events, and prescription refill information. After identification and recruitment of eligible patients, phone call check ins will occur every 3 months to assess side effects, risk factors, STI screening needs, and medication access. After checking in, the patient can drop by the clinic for required labs at their convenience, and the prescription can be renewed. Success of the program will be evaluated by monitoring retention and follow up rates, and patient satisfaction surveys. Secondary outcomes will include adverse effects of the medications, and adherence to medication via proportion of days covered. Qualitative analysis will be conducted to analyze retention rates. Patient satisfaction surveys will be conducted using a Likert-Scale rating.